Orchid Pharma: Monitoring Agency Report for Q2 FY27
Orchid Pharma Ltd has submitted its Monitoring Agency Report for the quarter ended September 30, 2026, concerning the utilization of proceeds from its Qualified Institutions Placement (QIP) of Rs. 400 crores. The report, issued by CARE Ratings Limited, indicates no deviation from the stated objects of the issue. However, the company has revised the allocation of QIP proceeds among the objects, with shareholder approval obtained via an AGM resolution on September 20, 2025. Notably, there is a significant delay in the implementation of the manufacturing facility in Jammu, with commercial operations now expected by February 2027. The allocation towards investment in Orchid Bio Pharma for the manufacturing facility has increased, while the allocation for repayment of borrowings has also risen. Conversely, the allocation towards the API facility at Alathur has been reduced.
Key Highlights
- Monitoring Agency Report for Q2 FY27 submitted by Orchid Pharma.
- No deviation in utilization of QIP proceeds from stated objects.
- Allocation of QIP funds revised with shareholder approval.
- Significant delay in Jammu manufacturing facility; operations expected Feb 2027.
- Increased allocation for Jammu facility and debt repayment.
Price Impact
More from ORCHPHARMA